Advancing Nanobiotechnology

           for Novel siRNA Therapeutics

Advisory Board

James A. Mixson, M.D.
Dr. Mixson is a Scientific Founder of Sirnaomics and Professor at the University of Maryland. He is an expert in cancer, polymer design and drug delivery. He spearheaded the HK (histidine-lysine) polymer nanoparticle technology for siRNA delivery in vitro and in vivo which is now demonstrating tremendous potential in delivery of RNAi therapeutics. Dr. Mixson’s laboratory is developing novel gene targeting approaches for treating cancer. He received his B.A. from Vanderbilt University, and his M.D. degree from Emory University.
Xiaochang (Don) Dai, Ph.D.

Dr. Dai received his Ph.D. in Chemistry from The Scripps Research Institute, followed by postdoctoral studies at California Institute of Technology. He then became an entrepreneur founding and supporting successful companies in China, including KBN, a JV by TEVA, then KPC, a public company recognized for being the first to bring Nobel Prize winning discovery Artemisinin to commercialization.  Dr. Dai brings a high level of entrepreneurial energy and acumen, combined with deep understanding of the company's underlying science and technology.

Brian Harvey, M.D., Ph.D.
Dr. Brian Harvey is a former Vice President of U.S. Regulatory Strategy at Pfizer. He also worked at the USFDA as Director of the Division of Gastroenterology Products. Dr. Harvey led the regulatory review for NDA and BLA submissions of major breakthrough drugs, including Humira, Remicade and Lialda. Throughout his FDA career, Dr. Harvey remained a practicing clinician at the Anne Arundel Medical Center in Maryland. He graduated with honors from Middlebury College in Vermont and earned his Ph.D. and M.D. at the University of Connecticut.
Pei-Jer Chen, M.D., Ph.D.
Professor Chen holds several faculty positions at the National Taiwan University, including Professor of Medicine and Director of the Medical College. His areas of expertise and research interests include molecular biology of hepatic viruses, treatment of liver cancers and prevention and treatment of other hepatic diseases. Dr. Chen received his M.D, from National Taiwan University and Ph.D. from University of Pennsylvania Medical School. He is a Member of National Academia of Taiwan (Academia Sinica).
Daniel D. Von Hoff, M.D., F.A.C.P.
Dr. Von Hoff is a Physician in Chief and a Distinguished Professor at the Translational Genomics Research Institute (TGen) in Phoenix, Arizona. He also holds the Virginia G. Piper Distinguished Chair for Innovative Cancer Research at HonorHealth Clinical Research Institute and Medical Director of Research at McKesson Specialty Health and the Chief Scientific Officer for US Oncology Research specializing in phase I clinical trials. He is also Professor of Medicine at Mayo Clinic Scottsdale, AZ.  Dr. Von Hoff’s major interest is in the development of new anticancer agents. He is the past President of the American Association for Cancer Research, a Fellow of the American College of Physicians, and a member and past board member of the American Society of Clinical Oncology.

© 2007-2021 by Sirnaomics, Inc.